Alzheimer's disease (AD) is the most common form of degenerative dementia and is
characterized by progressive impairment in cognitive function during mid-to late-adult life …

Alzheimer's disease (AD) is the most prevalent form of dementia. Despite decades of
research following several theoretical and clinical lines, all existing treatments for the …

Previous experiments have found that individuals with Alzheimer's disease (AD) show
increased activity in prefrontal regions compared with healthy age-matched controls during …

Background: Cholinesterase inhibitors (ChEIs) are the only drugs marketed for the treatment
of Alzheimer's disease. Despite numerous randomized controlled trials, the efficacy and …

Background Reduced cerebral blood flow (CBF) contributes to the pathophysiology of
Alzheimer's disease (AD). However, it is unclear whether there is a spatial-temporal-specific …

Donepezil is the leading compound for the treatment of Alzheimer's disease (AD) in more
than 50 countries. As compared with other conventional acetylcholinesterase inhibitors …

Target-based drug discovery is the dominant paradigm of drug discovery; however, a
comprehensive evaluation of its real-world efficiency is lacking. Here, a manual systematic …

Alzheimer's disease (AD) and vascular dementia (VaD) are widely accepted as the most
common forms of dementia. Cerebrovascular lesions frequently coexist with AD, creating an …

OBJECTIVE: The only approved pharmacological approach for the symptomatic treatment of
Alzheimer's disease in Japan is the use of a cholinesterase inhibitor, donepezil …

Structural MRI and functional imaging by SPECT as well as 18F-FDG PET are widely used
in the diagnosis of Alzheimer's disease (AD). Metabolic and perfusion reductions in the …